---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-137930"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T08:04:00.461517+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation; highlights 212Pb pipeline with Phase 1/2a data in 2026

## Summary
- Phase 1/2a data for VMT-α-NET in neuroendocrine tumors shows durable disease control and best-in-class safety profile.
- VMT01 (212Pb-MC1R) for melanoma shows preliminary anti-tumor activity and tolerability; combination with checkpoint inhibitors planned.
- PSV359 targeting FAP-α for solid tumors demonstrates improved tumor retention; Phase 1/2a trial ongoing.
- Phase 1/2 data expected across all three clinical programs in 2026.
- Proprietary Pb-based chelator and Lead-212 isotope platform designed to optimize therapeutic index.

## SEC filing metadata
- accession: 0001193125-26-137930
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526137930/0001193125-26-137930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526137930/catx-20260401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-137930
- JSON: https://secwatch.observer/filing/0001193125-26-137930.json
- Plain text: https://secwatch.observer/filing/0001193125-26-137930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.